SLGL (sol-gel.com) Enterprise Value-to-Sales Ratio

Sol-Gel Technologies focuses on treating rosacea and acne through unique substance encapsulation. After evaluating the EV/Sales history on GURU.Markets, we find that the 92673.61 mark reflects the current state of enterprise value to revenue. Growth relies on the implementation of patented silica microcapsules. However, supply chain disruptions and sanctions limit access to foreign patients and technologies.
Financial and market metric breakdowns for Sol-Gel (SLGL)

To filter for high-quality assets, investors utilize EV/Sales, which assesses the total enterprise value regardless of debt load per unit of revenue. This metric determines the market premium for intellectual property, which in the case of Sol-Gel Technologies (SLGL) reflects the capitalization of unique drug encapsulation patents, while this EV/Sales chart visualizes the valuation's resilience to FDA regulatory risks.